TI
APRE icon

Trexquant Investment’s Aprea Therapeutics APRE Stock Holding History

Trexquant Investment’s Portfolio APRE Stock Details APRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,268
Closed -$129K – 1072
2021
Q1 		$129K Buy
+1,268
New +$148K 0.01% 1033

Other funds holding APRE

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SG Americas Securities
SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Voloridge Investment Management
Voloridge Investment Management Jupiter, Florida $25B AUM 28.08% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return

Trexquant Investment's APRE Position: Q2 2021 in Review

Trexquant Investment sold out of Aprea Therapeutics (APRE) in Q2 2021, closing a stake of 1,268 shares — an estimated $129K sold.

Trexquant Investment first reported a position in APRE in Q1 2021 and held it in 1 quarter. The position peaked at $129K in Q1 2021. 50 funds tracked by Wall St. Rank hold APRE as of Q2 2021.

  • Trexquant Investment reported no remaining Aprea Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Trexquant Investment sold 1,268 Aprea Therapeutics shares in Q2 2021, an estimated $129K.
  • Trexquant Investment first reported a position in Aprea Therapeutics in Q1 2021 and held it in 1 quarter.
  • Trexquant Investment's Aprea Therapeutics position peaked at $129K in Q1 2021.
  • 50 funds tracked by Wall St. Rank held Aprea Therapeutics as of Q2 2021.

Based on Trexquant Investment's 13F filing for Q2 2021, filed 12 Aug 2021.